Literature DB >> 16961634

Factors associated with multidrug-resistant bacteria in secondary peritonitis: impact on antibiotic therapy.

P Seguin1, B Laviolle, C Chanavaz, P-Y Donnio, A-L Gautier-Lerestif, J-P Campion, Y Mallédant.   

Abstract

Secondary peritonitis includes community-acquired and nosocomial peritonitis. These intra-abdominal infections have a common pathogenesis but some microbiological differences, particularly with respect to the type of bacteria recovered and the level of antimicrobial susceptibility. This report describes a prospective observational study of 93 consecutive patients with secondary peritonitis during an 11-month period. Community-acquired peritonitis accounted for 44 cases and nosocomial peritonitis for 49 cases (post-operative in 35 cases). Fifteen multidrug-resistant (MDR) bacteria were recovered from 14 patients. In univariate analysis, the presence of MDR bacteria was associated significantly with pre-operative and total hospital lengths of stay, previous use of antimicrobial therapy, and post-operative antimicrobial therapy duration and modifications. A 5-day cut-off in length of hospital stay had the best specificity (58%) and sensitivity (93%) for predicting whether MDR bacteria were present. In multivariate analysis, only a composite variable associating pre-operative hospital length of stay and previous use of antimicrobial therapy was a significant independent risk-factor for infection with MDR bacteria. In conclusion, knowledge of these two factors may provide a more rational basis for selecting initial antimicrobial therapy for patients with secondary peritonitis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16961634     DOI: 10.1111/j.1469-0691.2006.01507.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  23 in total

1.  Are enterococci playing a role in postoperative peritonitis in critically ill patients?

Authors:  P Seguin; C Brianchon; Y Launey; B Laviolle; N Nesseler; P-Y Donnio; Y Malledant
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-11-12       Impact factor: 3.267

Review 2.  [Antimicrobial and antimycotic therapy of intra-abdominal infections].

Authors:  P Kujath; M Hoffmann; A Rodloff
Journal:  Chirurg       Date:  2008-04       Impact factor: 0.955

Review 3.  [Special aspects of postoperative complications following visceral surgery].

Authors:  H Bartels
Journal:  Chirurg       Date:  2009-09       Impact factor: 0.955

4.  Canadian practice guidelines for surgical intra-abdominal infections.

Authors:  Anthony W Chow; Gerald A Evans; Avery B Nathens; Chad G Ball; Glen Hansen; Godfrey Km Harding; Andrew W Kirkpatrick; Karl Weiss; George G Zhanel
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

5.  Antibiotic duration can be shortened in postoperative intra-abdominal infection.

Authors:  Im-Kyung Kim; Jae Gil Lee
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

Review 6.  Secondary peritonitis: principles of diagnosis and intervention.

Authors:  James T Ross; Michael A Matthay; Hobart W Harris
Journal:  BMJ       Date:  2018-06-18

7.  Therapeutic management of peritonitis: a comprehensive guide for intensivists.

Authors:  P Montravers; S Blot; G Dimopoulos; C Eckmann; P Eggimann; X Guirao; J A Paiva; G Sganga; J De Waele
Journal:  Intensive Care Med       Date:  2016-03-16       Impact factor: 17.440

Review 8.  [Complicated intra-abdominal infections: pathogens, resistance. Recommendations of the Infectliga on antbiotic therapy].

Authors:  K-F Bodmann
Journal:  Chirurg       Date:  2010-01       Impact factor: 0.955

9.  A focus on intra-abdominal infections.

Authors:  Massimo Sartelli
Journal:  World J Emerg Surg       Date:  2010-03-19       Impact factor: 5.469

10.  Risk factors for multidrug resistant bacteria and optimization of empirical antibiotic therapy in postoperative peritonitis.

Authors:  Pascal Augustin; Nathalie Kermarrec; Claudette Muller-Serieys; Sigismond Lasocki; Denis Chosidow; Jean-Pierre Marmuse; Nadia Valin; Jean-Marie Desmonts; Philippe Montravers
Journal:  Crit Care       Date:  2010-02-15       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.